Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 11/20 | 0.51 |
| ▸ | PROKR1 | Q8TCW9 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21145389 | 1.00 | USP30 (0.51) | USP30PROKR1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL29679555 | 0.86 | USP30 (0.46) | USP30 | |
| SCHEMBL21145375 | 0.85 | USP30 (0.53) | USP30PROKR1ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL21145374 | 0.85 | USP30 (0.53) | USP30PROKR1ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL21145395 | 0.84 | USP30 (0.74) | USP30 | |
| SCHEMBL21145394 | 0.80 | USP30 (0.75) | USP30ALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL21145373 | 0.79 | USP30 (0.72) | USP30ALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL21145371 | 0.79 | USP30 (0.72) | USP30ALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL21145398 | 0.74 | USP30 (0.43) | USP30ALDH1A1SMN1; SMN2LMNAHPGD | |
| SCHEMBL21145396 | 0.74 | USP30 (0.43) | USP30ALDH1A1SMN1; SMN2LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109790148-B | Cyano-substituted heterocycles having USP30 inhibitor activity | 特殊治疗有限公司 | 2022-06-07 | — | — | CN | disclosed |
| EP-3519397-B1 | CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LTD (GB) | 2021-05-19 | — | — | EP | disclosed |
| US-10927110-B2 | Cyano-subtituted heterocycles with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-02-23 | — | — | US | disclosed |
| US-20190218215-A1 | CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218215-A1 | CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | USP30, USP28, USP1 | USP30 1/4885PROKR1 4475/4885ALDH1A1 755/4885 |
| US-10927110-B2 | Cyano-subtituted heterocycles with activity as inhibitors of USP30 | USP30, USP28, USP1 | USP30 1/4885PROKR1 4475/4885ALDH1A1 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.